Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptors (CARs) are engineered receptors that direct T cells to target specific cell-surface antigens, enhancing their function and persistence.
• Mesothelin is a cell-surface antigen frequently overexpressed in various solid tumors, including mesothelioma, lung, pancreas, breast, and ovarian cancers, making it a potential therapeutic target.
• While mesothelin is crucial for tumor invasion, its low expression in healthy mesothelial cells necessitates careful therapeutic design.

Purpose of the Study:

• To review the potential of mesothelin-targeted CAR T-cell therapy for treating solid malignancies.
• To evaluate the efficacy and safety of mesothelin CAR therapy based on preclinical models and early clinical findings.

Main Methods:

• Review of preclinical CAR therapy models involving systemic or regional T-cell delivery targeting mesothelin.
• Analysis of recent clinical trial data for active immunization or immunoconjugates targeting mesothelin in pancreatic adenocarcinoma and mesothelioma.

Main Results:

• Preclinical models support the use of mesothelin CAR T-cell therapy in solid tumors.
• Early clinical trials involving mesothelin-targeted interventions have shown promising responses with no observed toxicity in patients with pancreatic adenocarcinoma or mesothelioma.

Conclusions:

• The success of CAR T-cell therapy in hematologic malignancies provides a strong rationale for exploring similar strategies in solid tumors.
• Mesothelin CAR T-cell therapy holds significant potential for treating a wide range of solid malignancies due to mesothelin's broad expression profile in these cancers.